Zevra Therapeutics (ZVRA) announced that its CFO and treasurer, R. LaDuane Clifton, will be stepping down from his position with the company, effective December 31 in order to pursue other professional opportunities. The company has initiated a search to identify its next chief financial officer.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZVRA:
- Zevra Therapeutics: Strategic Focus on Miplyffa Drives Buy Rating Amid Promising Growth Prospects
- Zevra Therapeutics Reports Strong Q3 Earnings and Strategic Growth
- Zevra Therapeutics price target lowered to $24 from $29 at Cantor Fitzgerald
- Zevra Therapeutics price target lowered to $24 from $25 at Canaccord
- Zevra Therapeutics: Strong Q3 Performance and Promising Pipeline Justify Buy Rating